Protection from lethal murine graft-versus-host disease without compromise of alloengraftment using transgenic donor T cells expressing a thymidine kinase suicide gene

Blood

Volumn 97, Issue 8, 2001, Pages 2506-2513

  Drobyski, W R ^a   Morse III, H C ^a   Burns, W H ^a   Casper, J T ^a   Sandford, G ^a  

^a FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; GANCICLOVIR; THYMIDINE KINASE;

ADOPTIVE TRANSFER; ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CHIMERA; CONTROLLED STUDY; FEMALE; GENE CONSTRUCT; GENE EXPRESSION; GENE TARGETING; GRAFT VERSUS HOST REACTION; LETHALITY; LYMPHOCYTE DEPLETION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SUICIDE GENE; T LYMPHOCYTE; TRANSGENE;

EID: 0035871695     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.8.2506     Document Type: Article

References (41)

1. An absence of T cells in murine bone marrow allografts leads to an increased susceptibility to rejection by natural killer cells and T cells
2. Donor-type activated natural killer cells promote marrow engraftment and B cell development during allogeneic bone marrow transplantation
3. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: Potential implications for marrow transplantation in humans
4. Graft failure in patients receiving T cell depleted HLA-identical allogeneic marrow transplants
5. Graft rejection in recipients of T-cell depleted HLA-nonidentical marrow transplants for leukemia
6. Graft failure after T-cell depleted human leukocyte antigen identical marrow transplants for leukemia, II: In vitro analyses of host effector mechanisms
7. Bone marrow transplantation across major histocompatibility barriers, V: Protection of mice from lethal graft-versus-host disease by pretreatment of donor cells with monoclonal anti-Thy 1.2 coupled to the toxin ricin
8. Elimination of graft-versus-host disease by in vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (Campath-1)
9. Role of T cell subsets in lethal graft-versus-host disease directed to class I versus class II H-2 differences, I: L3T4+ cells can either augment or retard GVHD elicited by Lyt-2+ cells in class I-different hosts
10. T cell subsets and graft-versus-host disease
11. Cytokine dysregulation and acute graft-versus-host disease
12. Kinetics of natural killer cell cytotoxicity during the graft-versus-host reaction. Relationship between natural killer cell activity, T and B cell activity, and development of histopathological alterations
13. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease
14. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease
15. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings
16. Transplantation for acute leukemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells
17. Depletion of donor lymphocytes by counterflow centrifugation successfully prevents acute graft-versus-host disease in matched allogeneic marrow transplantation
18. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomized study of two irradiation regimens
19. Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: An approach for specific in vivo donor T cell depletion after BMT?
20. Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir
21. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
22. Inhibition of graft-versus-host disease: Use of a T cell-controlled suicide gene
23. Prevention of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes
24. Ecdysone-inducible gene expression in mammalian cells and transgenic mice
25. Growth of AKR T cell leukemia lymphoblasts in medium containing interleukin 2
26. Loss of normal thymic repertoire selection and persistence of autoreactive T cells in graft-versus-host disease
27. Involvement of donor T cell cytotoxic effector mechanisms in preventing allogeneic marrow graft rejection
28. + thymocytes
29. Enhancement of bone marrow allografts from nude mice into mismatched recipients by T cells void of graft-versus-host activity
30. Prevention of allogeneic marrow graft rejection by donor T cells that do not recognize recipient alloantigens: Potential role of a veto mechanism
31. A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients
32. The immune system: Effector and target of graft-versus-host disease
33. The effect of graft-versus-host disease on T cell production and homeostasis
34. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy
35. Reactivity of hybridomas derived from T cells activated in vivo during graft-versus-host disease
36. Bone marrow transplantation across major histocompatibility barriers in mice, II: T cell requirement for engraftment in total lymphoid irradiation-conditioned recipients
37. A correlation between conditioning and engraftment in recipients of MHC-mismatched T celldepleted murine bone marrow transplants
38. Abrogation of bone marrow allograft resistance in mice by increased total body irradiation correlates with eradication of host clonable T cells and alloreactive cytotoxic precursors
39. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
40. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases